LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
07/27/2026
Back to search
Official data from USPTO
ONCOSIGNATURE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
50
Latest update
08/17/2026
Trademark type
Combined
Nice classes
5, 42
Filing date
09/22/2017
Registration date
04/09/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/10/2026
Last transaction
08/17/2026
Responsible office
United States Patent and Trademark Office
Status code
707
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
Watertown Massachusetts, US
Examiner
CORWIN, CHARLOTTE K
Current location
Historical data usage
Mark description
The mark consists of the stylized wording "ONCOSIGNATURE" with "ONCO" in orange and "SIGNATURE" in blue. Above the wording are two interlocked circles, each consisting of an outer border of small blue circles and an inner layer of larger orange circles.
Holders and representatives
Holders
Acrivon Therapeutics Inc.
OncoSignature AB
Representatives
Sara M. Bauer Womble Bond Dickinson (US) LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for use in oncologyspecifically the preventionalleviation and treatment of cancer and precancerous diseases and benign tumors; medical preparations for use in oncologyspecifically the preventionalleviation and treatment of cancer and precancerous diseases and benign tumors; veterinary pharmaceutical preparations for use in oncologyspecifically the preventionalleviation and treatment of cancer and precancerous diseases and benign tumors; pharmaceutical and medical preparations for treatmentprevention and alleviation of cancer; pharmaceutical and medical preparations for the prediction of drug treatment efficacy; pharmaceutical and medical preparations for prognosis related to cancer; biological preparations for medical and veterinary purposesfor use in oncologyspecifically the preventionalleviation and treatment of cancer and precancerous diseases and benign tumors; diagnostic kits consisting primarily of monoclonal antibodies for use in disease testingspecifically in oncology and premalignant disorders and benign tumors; chemical preparations for therapeutic usefor pharmaceutical or medical purposesfor use in oncologyspecifically the preventionalleviation and treatment of cancer and precancerous diseases and benign tumors; reagents for medical usefor medical diagnosisdrug-tailored efficacy prediction and/or analysis; clinical medical reagents; diagnostic preparations for medical and veterinary purposes; diagnostic test materials for medical use in the field of oncology in the form of a clinical biomarker signature assay on biopsy or other patient sample material for measuring biomarkers reflective of disease-driving processes that the drug inhibits and does not inhibit to predict treatment efficacy within oncology; diagnostic preparations for medical use; diagnostic biomarker reagents for medical purposes; companion diagnostic biomarker reagents for medical purposes
Class 42
Scientific and technological research and consultation servicesin the medical * and pharmaceutical research fields of drug-tailoredefficacy-predictive biomarkerspharmacodynamic biomarkerspatient responder identificationindication finding * pharmaceuticalscientific research fields of drug-tailoredefficacy-predictive biomarkerspharmacodynamic biomarkersdrug repurposingidentification of rational drug combinations ; industrial analysis and research servicesindustrial research in the field of oncology * biomarkers and predictive modeling; * basic medical research and medical clinical researchhereunder for development of therapeutics * using biomarkers and predictive modeling; * drug discovery services * in the medical and pharmaceutical research fields of drug-tailored efficacy-predictive biomarkerspatient responder identificationpharmacodynamic biomarkers and indication finding; * consultancy in the field of pharmaceutical research and development * services in the medical and pharmaceutical research fields of drug-tailored efficacy-predictive biomarkerspatient responder identificationpharmacodynamic biomarkers and indication finding; * medical and scientific research related to cancer and cancer therapyincluding research related to treatmentprevention and alleviation of cancer * in the medical and pharmaceutical research fields of drug-tailored efficacy-predictive biomarkspatient responder identificationpharmacodynamic biomarkers and indication finding; * pharmaceutical research services related to prediction of drug treatment efficacy * using biomarkers and predictive modeling; * medical research services related to cancer diagnosiscancer prognosis and drug-tailored efficacy prediction * using biomarkers and predictive modeling; * medical researchanalysis related to cancer diagnosiscancer prognosis and drug-tailored efficacy prediction * using biomarkers and predictive modeling *
Publications
History of USPTO decisions and trademark events.
50 publications found
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
07/24/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/24/2026
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
02/10/2026
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
02/10/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/09/2026
ES71
TEAS SECTION 71 RECEIVED
10/07/2025
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
04/18/2025
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
03/12/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/04/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
04/09/2024
CHLD
CHANGE OF OWNER RECEIVED FROM IB
02/26/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
07/13/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/13/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
07/13/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/13/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/13/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
07/13/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/16/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/31/2019
FIMP
FINAL DISPOSITION PROCESSED
07/31/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/09/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
04/09/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/25/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/25/2019
GPNX
NOTIFICATION PROCESSED BY IB
01/25/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/22/2019
PUBO
PUBLISHED FOR OPPOSITION
01/22/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/09/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/09/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/02/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/17/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
12/13/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/13/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
12/13/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/13/2018
DOCK
ASSIGNED TO EXAMINER
08/27/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/03/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/03/2018
ALIE
ASSIGNED TO LIE
08/02/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/18/2018
RFNT
REFUSAL PROCESSED BY IB
02/03/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/18/2018
RFRR
REFUSAL PROCESSED BY MPU
01/18/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/06/2018
MAFR
APPLICATION FILING RECEIPT MAILED
01/06/2018
CNRT
NON-FINAL ACTION WRITTEN
01/05/2018
DOCK
ASSIGNED TO EXAMINER
01/02/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/02/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/28/2017
Continuous trademark protection
Get notified about every new filing that threatens ONCOSIGNATURE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.